GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PharmChem Inc (OTCPK:PCHM) » Definitions » Net Income Including Noncontrolling Interests

PharmChem (PharmChem) Net Income Including Noncontrolling Interests : $0.22 Mil (TTM As of Sep. 2023)


View and export this data going back to 2003. Start your Free Trial

What is PharmChem Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

PharmChem's Net Income Including Noncontrolling Interests for the three months ended in Sep. 2023 was $0.22 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2023 was $0.22 Mil.


PharmChem Net Income Including Noncontrolling Interests Historical Data

The historical data trend for PharmChem's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmChem Net Income Including Noncontrolling Interests Chart

PharmChem Annual Data
Trend Dec93 Dec94 Dec95 Dec96 Dec97 Dec98 Dec99 Dec00 Dec01 Dec02
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 2.80 1.36 -8.48 3.34

PharmChem Quarterly Data
Jun99 Sep99 Dec99 Mar00 Jun00 Sep00 Dec00 Mar01 Jun01 Sep01 Dec01 Mar02 Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Sep22 Sep23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -0.56 0.25 0.22 0.22

PharmChem Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmChem Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of PharmChem's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmChem (PharmChem) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2411 E. Loop 820 N, Fort Worth, TX, USA, 76118
PharmChem Inc is engaged in selling and distributing of the PharmChek Sweat Patch Device. PharmChek is a system that uses sweat to detect the presence of illegal drugs. It consists of a transparent polyurethane outer covering, a small absorbent pad, and a release liner. Geographically the activities are carried out throughout the United States.
Executives
Alto Investors Palo 10 percent owner 470 UNIVERSITY AVENUE, PALO ALTO CA 94301
Micro Cap Partners Lp 10 percent owner

PharmChem (PharmChem) Headlines

From GuruFocus

PharmChem (PCHM) Announces Response To Opposition

By PRNewswire PRNewswire 08-11-2021